NCT05576831 STRatIfication of Vulvar Squamous Cell Carcinoma by HPV and p53 Status to Guide Excision
| NCT ID | NCT05576831 |
| Status | Recruiting |
| Phase | — |
| Sponsor | British Columbia Cancer Agency |
| Condition | Vulvar Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 249 participants |
| Start Date | 2024-11-25 |
| Primary Completion | 2031-11-25 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 249 participants in total. It began in 2024-11-25 with a primary completion date of 2031-11-25.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Vulvar cancer affects the external genitalia of women. This type of cancer is uncommon, arising mostly in older women and has been neglected in research and clinical trials. Over the recent years, investigators have learned that the most common type of vulvar cancer; vulvar squamous cell carcinoma (VSCC) develops from pre-cancerous lesions via different pathways. One pathway is associated with human papillomavirus (HPV) infection, and another is related to chronic inflammatory skin conditions (and not HPV). The VSCCs arising from these two principal pathways; HPV- associated (HPV A) and HPV-independent (HPV I), behave differently with different risks of recurrence, and different response to treatments. HPV-I VSCC are further defined by mutations in TP53 (Tumor Protein 53), which identify a group of patients with aggressive disease. Currently treatment is the same for all women with vulvar cancer, and consequently many women may be overtreated, and many women are not treated enough. Given evolving knowledge of this disease, this 'one size fits all' approach may no longer be appropriate. The investigators aim in this study is to see if personalizing surgical therapy for patients with vulvar cancer based on HPV and TP53 status will improve outcomes.
Eligibility Criteria
Inclusion Criteria: * Histologically confirmed primary diagnosis of vulvar squamous cell carcinoma * Surgically staged FIGO (International Federation of Gynaecology and Obstetrics) I-II disease * Margin status after primary surgery: * HPV-I VSCC: margins are negative for cancer but \<8mm, and/or positive for dVIN, and/or positive for p53 abnormality on IHC * HPV-A VSCC: margins are negative for cancer but \<8mm (regardless of in-situ (HSIL) margin status) * Age ≥18 years old * Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each patient must sign a consent form prior to enrollment in the trial to document their willingness to participate. A similar process must be followed for sites outside of Canada as per their respective cooperative group's procedures. Exclusion Criteria: * Recurrent vulvar squamous cell carcinoma * Non-squamous cell carcinoma histotypes * FIGO stage III- IV disease * Patients referred for adjuvant radiation for close margins * Margins positive for cancer
Contact & Investigator
Amy Jamieson, MD
PRINCIPAL INVESTIGATOR
BC Cancer
Frequently Asked Questions
Who can join the NCT05576831 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Vulvar Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05576831 currently recruiting?
Yes, NCT05576831 is actively recruiting participants. Contact the research team at Amy.Jamieson@vch.ca for enrollment information.
Where is the NCT05576831 trial being conducted?
This trial is being conducted at Vancouver, Canada.
Who is sponsoring the NCT05576831 clinical trial?
NCT05576831 is sponsored by British Columbia Cancer Agency. The principal investigator is Amy Jamieson, MD at BC Cancer. The trial plans to enroll 249 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.